Grifols (GRFS) Cash from Operations Growth (5y) (2015 - 2020)
Grifols (GRFS) Cash from Operations Growth (5y) (2015 - 2020) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 24.71% |
| Dec 31, 2019 | 19.71% |
| Mar 31, 2019 | -25.51% |
| Dec 31, 2018 | 8.66% |
| Jun 30, 2018 | -5.31% |
| Mar 31, 2018 | -1.36% |
| Dec 31, 2017 | 26.65% |
| Jun 30, 2017 | -1.43% |
| Mar 31, 2017 | 330.59% |
| Dec 31, 2016 | -1.92% |
| Sep 30, 2016 | 29.71% |
| Dec 31, 2015 | 50.54% |
| Sep 30, 2015 | 38.07% |